Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease

American Journal of Cardiology

Volumn 90, Issue 7, 2002, Pages 784-786

  Lund, Tor M ^a   Torsvik, Harald ^a   Falch, Dagfinn ^a   Christophersen, B Jørn ^b   Skårdal, Rita ^a   Gullestad, Lars ^a  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DRUG EFFECT; EATING HABIT; ENDOCRINE DISEASE; FOLLOW UP; HEART INFARCTION; HUMAN; INFECTION; INFORMED CONSENT; LUNG DISEASE; MORBIDITY; PRIORITY JOURNAL; RANK SUM TEST; STUDENT T TEST; TIME; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CIRCADIAN RHYTHM; CORONARY ARTERIOSCLEROSIS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0036804616     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02614-0     Document Type: Article

References (13)

1. Polsker G.L., McTavish D. Simvastatin, a reapraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs. 50:1995;334-363.
2. Jones P.J.H., Schoeller D.A. Evidence ofor diurnal periodicity in human cholesterol synthesis. J Lipid Res. 31:1990;667-673.
3. Saito Y., Yoshida S., Nakaya N., Hata N., Hata Y., Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. Arterioscler. Thromb. 11:1991;816-826.
4. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
5. Rosenson R.S., Tangeney C.C. Antithrombotic properties of statins. Implications for cardiovascular event reduction. JAMA. 279:1998;1643-1650.
6. Eda S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in sensitivity and dynamic range. J Clin Lab Anal. 12:1998;137-144.
7. Altman DG. Practical Statistics for Medical Research. London, UK: Chapman and Hall, 1991:467-471.
8. Strandberg T.E., Vanhanen H., Tikkanen M.J. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Intern Med. 32:2000;579-583.
9. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE) a randomized trial and cohort study . JAMA. 286:2001;64-70.
10. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
11. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 23:2001;1296-1310.
12. Horne R. Compliance, adherence and concordance. Taylor K., Harding G., Pharmacy Practice. 2001;165-184 Taylor and Francis, London.
13. Ryan A.A. Medication compliance and older people a review of the literature . Int J Nursing. Studies. 36:1999;153-162.